Arcellx Announces Positive Phase 2 Study Results

Arcellx Inc ( (ACLX) ) just unveiled an announcement.

On May 14, 2025, Arcellx, Inc. announced positive results from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for patients with relapsed or refractory multiple myeloma. The study demonstrated a 97% overall response rate and a 68% complete response rate, with no delayed neurotoxicities observed. These findings will be presented at the EHA 2025 Congress, highlighting the potential of anito-cel to address unmet needs in multiple myeloma treatment. The company, in collaboration with Kite, plans to commercialize anito-cel, with a 2026 launch anticipated.

The most recent analyst rating on (ACLX) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Arcellx Inc stock, see the ACLX Stock Forecast page.

Spark’s Take on ACLX Stock

According to Spark, TipRanks’ AI Analyst, ACLX is a Neutral.

Arcellx Inc faces significant financial performance challenges with negative earnings and cash flow issues, balanced somewhat by strong cash reserves. Technical analysis indicates a bearish trend, and valuation metrics reflect typical growth-phase characteristics of biotech firms with negative earnings. Recent positive corporate events, including board changes, provide strategic growth potential.

To see Spark’s full report on ACLX stock, click here.

More about Arcellx Inc

Arcellx, Inc. is a clinical-stage biotechnology company focused on reimagining cell therapy by developing innovative immunotherapies for cancer and other incurable diseases. The company aims to create safer, more effective, and broadly accessible cell therapies, positioning itself as a forward pillar of medicine.

Average Trading Volume: 725,840

Technical Sentiment Signal: Sell

Current Market Cap: $3.28B

For an in-depth examination of ACLX stock, go to TipRanks’ Stock Analysis page.